Sophia Genetics (SOPH) announced a new milestone in the adoption of its cancer testing applications MSK-Access powered with Sophia DDM and MSK-Impact powered with Sophia DDM. Thirty-seven institutions have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks